XML 23 R79.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Business Segment Information - Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment (Detail) (USD $) In Thousands, unless otherwise specified | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | ---
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | $ 115,231 ofix_ContributionsMargin | $ 160,692 ofix_ContributionsMargin | $ 153,948 ofix_ContributionsMargin
General and administrative |  |  |  |  |  |  |  |  |  | 64,830 us-gaap_GeneralAndAdministrativeExpense | 53,650 us-gaap_GeneralAndAdministrativeExpense | 64,785 us-gaap_GeneralAndAdministrativeExpense
Research and development |  |  |  |  |  |  |  |  |  | 26,768 us-gaap_ResearchAndDevelopmentExpense | 28,577 us-gaap_ResearchAndDevelopmentExpense | 22,861 us-gaap_ResearchAndDevelopmentExpense
Amortization of intangible assets |  |  |  |  |  |  |  |  |  | 2,687 us-gaap_AmortizationOfIntangibleAssets | 2,298 us-gaap_AmortizationOfIntangibleAssets | 2,550 us-gaap_AmortizationOfIntangibleAssets
Costs related to the accounting review and restatement |  |  |  |  |  |  |  |  |  | 12,945 ofix_AccountingReviewAndRestatementCosts |  |
Impairment of goodwill |  |  |  |  |  |  |  |  | 19,193 us-gaap_GoodwillImpairmentLoss | 19,193 us-gaap_GoodwillImpairmentLoss |  |
Charges related to U.S. Government resolutions |  |  |  |  |  |  |  |  |  |  | 1,295 us-gaap_GainLossRelatedToLitigationSettlement | 57,141 us-gaap_GainLossRelatedToLitigationSettlement
Operating (loss) income | (10,079)us-gaap_OperatingIncomeLoss | (14,101)us-gaap_OperatingIncomeLoss | 6,920 us-gaap_OperatingIncomeLoss | 6,068 us-gaap_OperatingIncomeLoss | 26,518 us-gaap_OperatingIncomeLoss | 16,943 us-gaap_OperatingIncomeLoss | 16,622 us-gaap_OperatingIncomeLoss | 14,789 us-gaap_OperatingIncomeLoss |  | (11,192)us-gaap_OperatingIncomeLoss | 74,872 us-gaap_OperatingIncomeLoss | 6,611 us-gaap_OperatingIncomeLoss
BioStim [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Impairment of goodwill |  |  |  |  |  |  |  |  |  |  |  |
Biologics [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Impairment of goodwill |  |  |  |  |  |  |  |  |  |  |  |
Extremity Fixation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Impairment of goodwill |  |  |  |  |  |  |  |  | 9,825 us-gaap_GoodwillImpairmentLoss / us-gaap_StatementBusinessSegmentsAxis = ofix_ExtremityFixationMember |  |  |
Spine Fixation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Impairment of goodwill |  |  |  |  |  |  |  |  | 9,368 us-gaap_GoodwillImpairmentLoss / us-gaap_StatementBusinessSegmentsAxis = ofix_SpineFixationMember |  |  |
Operating Segments [Member] | BioStim [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | 63,847 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_BiostimMember | 88,788 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_BiostimMember | 92,860 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_BiostimMember
Operating Segments [Member] | Biologics [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | 24,794 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_BiologicsMember | 23,589 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_BiologicsMember | 18,978 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_BiologicsMember
Operating Segments [Member] | Extremity Fixation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | 23,704 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_ExtremityFixationMember | 34,554 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_ExtremityFixationMember | 30,773 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_ExtremityFixationMember
Operating Segments [Member] | Spine Fixation [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | 4,329 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_SpineFixationMember | 15,256 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_SpineFixationMember | 13,037 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_OperatingSegmentsMember / us-gaap_StatementBusinessSegmentsAxis = ofix_SpineFixationMember
Corporate, Non-Segment [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total net margin |  |  |  |  |  |  |  |  |  | 1,443 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_CorporateNonSegmentMember | 1,495 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_CorporateNonSegmentMember | 1,700 ofix_ContributionsMargin / us-gaap_ConsolidationItemsAxis = us-gaap_CorporateNonSegmentMember
Material Reconciling Items [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sales Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
General and administrative |  |  |  |  |  |  |  |  |  | 64,830 us-gaap_GeneralAndAdministrativeExpense / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember | 53,650 us-gaap_GeneralAndAdministrativeExpense / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember | 64,785 us-gaap_GeneralAndAdministrativeExpense / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember
Research and development |  |  |  |  |  |  |  |  |  | 26,768 us-gaap_ResearchAndDevelopmentExpense / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember | 28,577 us-gaap_ResearchAndDevelopmentExpense / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember | 22,861 us-gaap_ResearchAndDevelopmentExpense / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember
Amortization of intangible assets |  |  |  |  |  |  |  |  |  | 2,687 us-gaap_AmortizationOfIntangibleAssets / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember | 2,298 us-gaap_AmortizationOfIntangibleAssets / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember | 2,550 us-gaap_AmortizationOfIntangibleAssets / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember
Costs related to the accounting review and restatement |  |  |  |  |  |  |  |  |  | 12,945 ofix_AccountingReviewAndRestatementCosts / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember |  |
Impairment of goodwill |  |  |  |  |  |  |  |  |  | 19,193 us-gaap_GoodwillImpairmentLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember |  |
Charges related to U.S. Government resolutions |  |  |  |  |  |  |  |  |  |  | 1,295 us-gaap_GainLossRelatedToLitigationSettlement / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember | 57,141 us-gaap_GainLossRelatedToLitigationSettlement / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember
Operating (loss) income |  |  |  |  |  |  |  |  |  | $ (11,192)us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember | $ 74,872 us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember | $ 6,611 us-gaap_OperatingIncomeLoss / us-gaap_ConsolidationItemsAxis = us-gaap_MaterialReconcilingItemsMember

X
- Definition Accounting review and restatement costs. + References No definition available. + Details
Name: | ofix_AccountingReviewAndRestatementCosts
Namespace Prefix: | ofix_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contributions Margin + References No definition available. + Details
Name: | ofix_ContributionsMargin
Namespace Prefix: | ofix_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ofix_SalesInformationLineItems
Namespace Prefix: | ofix_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 + Details
Name: | us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13854-109267 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=ofix_BiologicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=ofix_BiostimMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=ofix_ExtremityFixationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=ofix_SpineFixationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |